MYOF (myoferlin) is a calcium/phospholipid-binding protein that functions primarily in plasma membrane repair and endocytic recycling 1. The protein contains a single transmembrane domain and regulates membrane transport processes including extracellular secretion, vesicle trafficking, and membrane receptor recycling 1. In normal physiology, MYOF mediates rapid resealing of mechanically disrupted membranes in endothelial cells and maintains lysosomal membrane integrity in pancreatic cancer cells 2. Clinically, MYOF mutations cause hereditary angioedema with normal C1-INH activity (MYOF-HAE), a rare autosomal dominant disorder characterized by recurrent angioedema episodes 3. Beyond genetic disease, MYOF is significantly overexpressed in multiple malignancies including lung, pancreatic, breast, and gastric cancers 1. High MYOF expression correlates with increased tumor invasion, poor prognosis, and enhanced cancer cell migration 45. In pancreatic ductal adenocarcinoma, MYOF promotes progression by stabilizing ILF3 protein, which enhances LCN2 expression and suppresses ferroptosis 5. In lung cancer, MYOF suppression by the E3 ligase TRIM8 reduces metastatic potential through decreased matrix metalloproteinase secretion 4. These findings suggest MYOF represents a promising therapeutic target for cancer treatment, with potential for small molecule inhibitors targeting its C2D domain.